We are part of the CSL Limited group of companies. See how we're Driven by Our Promise.
We collaborate with rare disease organizations to promote quality medical care and services.
We offer a variety of support programs and activities for the patients we serve.
We also aim to make sure that nothing holds you back from getting the therapies you need.
We work every day as if someone’s life depends on it, because it does.
We manufacture products to treat a number of rare diseases.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL Behring.
In episode 5, hear from Yann Le Cam, leader of Europe’s rare disease community, EURORDIS. In episode 6, experts explore the p…
Gene therapy marks a new era in the battle against genetic diseases. Learn more in a short video.
Debbie Drane, Senior Vice President of Commercial Development, moderates a panel on patient access to innovative treatments l…
More than 100 years ago, scientists started unlocking the mysteries of genes and inherited traits. Today, gene therapy holds …
We discuss ethical questions with expert Hervé Chneiweiss, who serves on the World Health Organization (WHO) committee that’s…
We get the patient perspective from advocate Durhane Wong-Rieger, who says there are many unknowns.
Two leaders in Europe say success will hinge on a unified patient registry, acceptance of real-world evidence and harmonized …
Ahead of this year’s Congress of the European Society of Gene and Cell Therapies, we talked with Luigi Naldini, a pioneer in …
Here are 5 things to know about this potential therapy.
CSL Behring’s planned laboratory in California will enhance innovation and collaboration near academic and research instituti…
Hemophilia B patients are missing clotting Factor IX but treatments have come a long way - with more innovation in progress.
CSL Behring’s R&D Head: We’re growing our capabilities in gene therapy to improve patients’ lives.
Popular search terms:
Americas
Asia Pacific
Middle East
Europe